Stealth BioTherapeutics Corp. ADS
MITO
MITO was delisted on the 15th of November, 2022.
15 hedge funds and large institutions have $752K invested in Stealth BioTherapeutics Corp. ADS in 2021 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
7% more funds holding
Funds holding: 14 → 15 (+1)
39% less capital invested
Capital invested by funds: $1.23M → $752K (-$473K)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GSC
Ground Swell Capital
Folly Beach,
South Carolina
|
+$19.7K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$16.9K |
| 3 |
Envestnet Asset Management
Chicago,
Illinois
|
+$12.9K |
| 4 |
Millennium Management
New York
|
+$4.38K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
+$2.41K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
-$26K |
| 2 |
SBL
Sargent Bickham Lagudis
Boulder,
Colorado
|
-$20K |
| 3 |
Renaissance Technologies
New York
|
-$10.2K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$1.24K |
| 5 |
Morgan Stanley
New York
|
-$1.04K |
MITO Hedge Fund Activity: Q4 2021 in Review
15 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Stealth BioTherapeutics Corp. ADS (MITO) for Q4 2021, worth a combined $752K — down 39% from $1.23M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new MITO positions and 3 closed out — a net gain of 1 holder — while 2 added to existing stakes and 4 trimmed.
The largest buyer was Ground Swell Capital, opening a new position worth an estimated $19.7K. The largest seller was HRT Financial, exiting entirely with an estimated $26K sold.
- 15 institutional investors held Stealth BioTherapeutics Corp. ADS (MITO) as of Q4 2021, up from 14 in Q3 2021.
- Funds reported $752K of Stealth BioTherapeutics Corp. ADS stock for Q4 2021, down 39% quarter-over-quarter.
- 4 funds opened new Stealth BioTherapeutics Corp. ADS positions in Q4 2021 and 3 closed out, a net change of +1 holder.
- The largest Stealth BioTherapeutics Corp. ADS buyer in Q4 2021 was Ground Swell Capital, an estimated $19.7K added.
- The largest Stealth BioTherapeutics Corp. ADS seller in Q4 2021 was HRT Financial, an estimated $26K sold.
Based on aggregated 13F filings for Q4 2021.